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Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002, and detailed phylogenetic and
epidemiological analyses have suggested that it originated from animals. The spike (S) glycoprotein has been
identified as a major component of protective immunity, and 23 different amino acid changes were noted during
the expanding epidemic. Using a panel of SARS-CoV recombinants bearing the S glycoproteins from isolates
representing the zoonotic and human early, middle, and late phases of the epidemic, we identified 23 mono-
clonal antibodies (MAbs) with neutralizing activity against one or multiple SARS-CoV spike variants and
determined the presence of at least six distinct neutralizing profiles in the SARS-CoV S glycoprotein. Four of
these MAbs showed cross-neutralizing activity against all human and zoonotic S variants in vitro, and at least
three of these were mapped in distinct epitopes using escape mutants, structure analyses, and competition
assays. These three MAbs (S109.8, S227.14, and S230.15) were tested for use in passive vaccination studies
using lethal SARS-CoV challenge models for young and senescent mice with four different homologous and
heterologous SARS-CoV S variants. Both S227.14 and S230.15 completely protected young and old mice from
weight loss and virus replication in the lungs for all viruses tested, while S109.8 completely protected mice from
weight loss and clinical signs in the presence of viral titers. We conclude that a single human MAb can confer
broad protection against lethal challenge with multiple zoonotic and human SARS-CoV isolates, and we
identify a robust cocktail formulation that targets distinct epitopes and minimizes the likely generation of
escape mutants.
In 2002 to 2003, a novel coronavirus (CoV) caused an out-
break of severe acute respiratory syndrome (SARS), which
infected more than 8,000 people and was associated with a
10% fatality rate (5, 19). In addition, several laboratory-
acquired cases of SARS-CoV infection including community
spread were reported in 2003 and 2004, highlighting a need for
therapeutics (25, 31). Old age (60 years) was significantly
associated with increased SARS-related deaths due to rapidly
progressive respiratory compromise (acute respiratory distress
syndrome) (5, 26, 40).
SARS-CoV is a zoonotic virus most likely originating from
Chinese horseshoe bats, amplified in palm civets and raccoon
dogs in the live-animal markets, and subsequently transmitted
to human populations (16). The 2003-2004 epidemic has been
divided into zoonotic, early, middle, and late phases based on
molecular epidemiological studies (6). Comparative analysis of
the SARS-CoV genomes from both human and zoonotic iso-
lates throughout the different phases of the epidemic showed a
high rate of evolution in the viral attachment protein, the spike
(S) glycoprotein, with 23 amino acid changes evolving over the
course of the epidemic (37).
Several studies have shown that the SARS-CoV S glycopro-
tein binds to the receptor angiotensin 1-converting enzyme 2
(ACE2), mediating viral entry (22, 52). A total of 18 amino
acids (aa) in ACE2 that are in contact with 14 residues in the
receptor binding domain (RBD) of SARS-CoV have been
identified (21). Two of these amino acids, aa 479 and 487, have
been shown to be critical in the binding of the RBD to human
ACE2 and to be linked to cross-species transmission to hu-
mans during the epidemic. Not surprisingly, the S glycoprotein
has also been identified as a major component of protective
immunity and is highly immunogenic, containing at least three
domains that are targeted by neutralizing antibodies (10, 13,
20). The exact number of neutralizing epitopes is unknown, as
is the effect on neutralization of the sequence variation in these
regions between the different S glycoproteins isolated during
the SARS-CoV epidemic.
Both human and murine monoclonal antibodies (MAbs)
have been developed against three late-phase SARS-CoV
strains, strains Urbani, Tor-2, and HKU-39849, and in vitro
neutralizing activity has been described (46–48). The recent
development of a method to isolate a large number of MAbs
from SARS patients provides the reagents needed to charac-
terize the homologous and heterologous neutralizing re-
sponses after natural SARS-CoV infection (47). Although
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studies using pseudotyped lentiviruses and recombinant
SARS-CoV RBD protein have shown some cross-neutralizing
or cross-reactive activity (12, 24, 43, 56, 57), the neutralizing
activities of these MAbs have not been tested against actual
heterologous SARS-CoV strains from the middle, early, or
zoonotic phase of the epidemic or in lethal models of disease.
This is potentially problematic, since the absence of human
cases over the past 2 years suggests that future epidemics will
likely result from zoonotic transmission. Consequently, anti-
bodies that provide robust cross-neutralization activity are es-
sential to interrupt zoonotic transmission and contain future
epidemics (3, 36).
Passive immunization studies on mice, ferrets, and hamsters
with select MAbs have demonstrated that some neutralizing
antibodies can successfully prevent or limit infection (35, 43,
45, 47). While prophylactic treatment can result in complete
protection of rodents from SARS-CoV infection, postinfection
treatment is usually less robust but significantly reduces viral
titers in the lung (35). To date, all studies have been performed
with young animals, allowing for virus replication in the ab-
sence of detectable clinical symptoms and disease (37, 42), so
it is not clear whether select antibodies will prevent clinical
disease or provide measurable levels of protection against ho-
mologous or heterologous lethal challenge, especially in more
vulnerable senescent populations.
Passive protection of senescent populations has also been
poorly studied, yet aged populations are most vulnerable to
severe and fatal SARS-CoV infections (5, 26, 40). In the aged
BALB/c mouse model, passive transfer of hyperimmune
SARS-CoV antiserum from mice prevented infection with the
homologous late-phase strain Urbani (51). The use of human
MAbs for prevention or treatment of lethal heterologous
SARS-CoV infection in aged populations, however, has not
been studied in detail. In addition, the recently reported vac-
cine failure in aged populations makes passive immunization
an attractive alternative (8).
We recently developed several lethal SARS-CoV challenge
models with BALB/c mice that recapitulated the age-related
clinical signs, weight loss exceeding 20% as well as severe lung
pathology, by using recombinant SARS-CoV bearing the S
glycoprotein of early human and zoonotic strains (37). A sec-
ond pathogenic model for young mice was also developed by
serial passage of the Urbani isolate in BALB/c mice, resulting
in MA15, which replicates to high titers in the lung and causes
clinical disease, weight loss exceeding 20%, and severe alve-
olitis (33). In the present study, we used a panel of isogenic
SARS-CoVs bearing human and zoonotic S glycoproteins to
categorize the human MAbs into six distinct neutralization
profiles. Moreover, we identify four neutralizing antibodies
that neutralize all zoonotic and human strains tested, and we
demonstrate that three of these MAbs engage unique epitopes
in the S glycoprotein, providing for the development of a
broad-spectrum therapeutic that protects young and senescent
mice from lethal homologous and heterologous challenge. A
cocktail of these antibodies would likely provide robust pro-
tection from lethal SARS-CoV infection in humans.
MATERIALS AND METHODS
Viruses and cells. The generation and characterization of the recombinant
infectious clones (ic) of Urbani—icCUHK-W1, icGZ02, icHC/SZ/61/03,
icA031G, and icMA15—have been described previously (33, 37). Briefly, the
Urbani spike gene in icUrbani was replaced by the various spike genes of
CUHK-W1, GZ02, HC/SZ/61/03, and A031G. All recombinant icSARS-CoV
strains were propagated on Vero E6 cells in Eagle’s minimal essential medium
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf serum (HyClone,
Logan, UT), kanamycin (0.25 g/ml), and gentamicin (0.05 g/ml) at 37°C in a
humidified CO2 incubator. All work was performed in a biological safety cabinet
in a biosafety level 3 laboratory containing redundant exhaust fans. Personnel
were equipped with powered air-purifying respirators with high-efficiency par-
ticulate air and organic vapor filters (3M, St. Paul, MN), wore Tyvek suits
(DuPont, Research Triangle Park, NC), and were double gloved.
Human MAbs. Human MAbs against SARS-CoV were generated as described
previously (47). The MAbs were initially screened for their capacity to bind to
SARS-CoV S-expressing cells and were subsequently tested for their ability to
neutralize the Frankfurt isolate of SARS-CoV (GenBank accession number
AY310120). A panel of 23 SARS-CoV S-specific MAbs and a control MAb
(D2.2) specific for diphtheria toxin were used for further study.
Neutralization assay. Neutralizing titers were determined by either a micro-
neutralization assay or a plaque reduction neutralization titer assay (37). For the
microneutralization assay, MAbs were serially diluted twofold and incubated
with 100 PFU of the different icSARS-CoV strains for 1 h at 37°C. The virus and
antibodies were then added to a 96-well plate with 5 103 Vero E6 cells/well and
5 wells per antibody dilution. Wells were checked for cytopathic effect (CPE) at
4 to 5 days postinfection, and the 50% neutralization titer was determined as the
MAb concentration at which at least 50% of wells showed no CPE. For the
plaque reduction neutralization titer assay, MAbs were serially diluted twofold
and incubated with 100 PFU of the different icSARS-CoV strains for 1 h at 37°C.
The virus and antibodies were then added to a 6-well plate with 5  105 Vero E6
cells/well in duplicate. After a 1-h incubation at 37°C, cells were overlaid with 3
ml of 0.8% agarose in medium. Plates were incubated for 2 days at 37°C and then
stained with neutral red for 3 h, and plaques were counted. The percentage of
neutralization was calculated as [1  (number of plaques with antibody/number
of plaques without antibody)]  100. All assays were performed in duplicate.
Importantly, a good correlation has been noted between the two assays (data not
shown).
Inhibition of binding of SARS-CoV spike glycoprotein to ACE2. Serial dilu-
tions of MAbs in phosphate-buffered saline (PBS)–1% fetal calf serum were
incubated for 20 min at 4°C with 5 g/ml SARS-CoV S glycoprotein (S1 domain,
aa 19 to 713 of the WH20 isolate [99.8% amino acid homology with Urbani];
accession number AY772062) fused to the Fc region of human immunoglobulin
(Ig) (Aalto Bio Reagents, Dublin, Ireland). The mixture was added to a single-
cell suspension of 4  104 ACE2-transfected DBT cells that had been sorted for
stable and relatively uniform levels of ACE2 expression. After 20 min, the cells
were washed and stained with phycoerythrin-conjugated F(ab)2 fragments of a
goat anti-human Fc specific antibody (Jackson ImmunoResearch Laborato-
ries). The percentage of binding inhibition was calculated as [1  (% positive
events for the sample/Bmax)]  100, where maximum binding (Bmax) is repre-
sented by the average of six wells. The concentration of the antibody needed to
achieve 50% binding inhibition was calculated with GraphPad Prism software
using nonlinear regression fitting with a variable slope.
Detection of human MAbs. The reactivities of MAbs with native or denatured
Urbani S recombinant protein were determined by enzyme-linked immunosor-
bent assays (ELISA). Briefly, 96-well plates were coated with 1 g/ml of recom-
binant Urbani S glycoprotein (NR-686; NIH Biodefense and Emerging Infec-
tions Research Resources Repository, NIAID, NIH). Wells were washed and
blocked with 5% nonfat milk for 1 h at 37°C and were then incubated with
serially diluted MAbs for 1.5 h at 37°C. Bound MAbs were detected by incubat-
ing alkaline phosphatase-conjugated goat anti-human IgG (A-1543; Sigma) for
1 h at 37°C and were developed by 1 mg/ml p-nitrophenylphosphate substrate in
0.1 M glycine buffer (pH 10.4) for 30 min at room temperature. The optical
density (OD) values were measured at a wavelength of 405 nm in an ELISA
reader (Bio-Rad model 680).
Competition for binding to SARS-CoV S glycoprotein. MAbs were purified on
protein G columns (GE Healthcare) and biotinylated using the EZ-Link NHS-
PEO solid-phase biotinylation kit (Pierce). An ELISA was used as described
above to measure the competition between unlabeled and biotinylated MAbs for
binding to immobilized SARS-CoV S glycoprotein. Unlabeled competitor MAbs
were added at 5 g/ml. After 1 h, biotinylated MAbs were added at a limiting
concentration (0.1 g/ml) that was chosen to give a net OD in the linear part of
the titration curve, allowing the inhibitory effects of the unlabeled MAb to be
quantitated. After incubation for 1 h, the plates were washed, and the amount of
biotinylated MAb bound was detected using alkaline phosphatase-labeled
streptavidin (Jackson ImmunoResearch). The percentage of inhibition was cal-
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culated with the means of triplicate tests as (1 [(ODsample ODnegative control)/
(ODpositive control  ODnegative control)])  100.
Escape mutant analysis. Thirty micrograms of a neutralizing antibody was
incubated with 1  106 PFU of icGZ02 for 30 min at room temperature in a
0.25-ml volume and was then inoculated onto six-well dishes containing 1  106
cells. After a 1-h incubation, the inoculating virus was removed, and 1 ml of
medium containing 30 g of the appropriate antibody was added to the culture
wells. The development of CPE was monitored over 72 h, and progeny viruses
were harvested at 25 to 50% CPE. Antibody treatment was repeated two
additional times, and more-rapid CPE was noted with each passage. Passage 3
viruses were plaque purified in the presence of a MAb, and neutralization-
resistant viruses were isolated and designated GZ02-230 and GZ02-109-1 and -2.
The S genes of individual plaques were sequenced as previously described (37).
The neutralization titers for wild-type and MAb-resistant viruses were deter-
mined as described above.
Structural analyses. The crystal structure coordinates of the SARS-CoV RBD
interacting with the human ACE2 receptor (PDB code 2AJF) (21) were used as
a template to generate each set of mutations using the Rosetta Design Web
server (http://rosettadesign.med.unc.edu/). In each case, the SARS-CoV RBD
structure was analyzed by using the molecular modeling tool MacPyMol
(DeLano Scientific) to determine which amino acid residues were proximal to
the amino acid being targeted for replacement. Briefly, each amino acid to be
altered was highlighted, and all other amino acid residues within an interaction
distance of 5 Å were identified. Using the Rosetta Design website, the amino acid
replacements were incorporated, and all amino acid residues within the 5-Å
interaction distance were relaxed to allow the program to repack the side chains
to an optimal energetic state. This process was repeated with each mutation and
series of mutations. Ten models were generated for each set of mutations, and
the best model was selected based on the lowest energy score and was further
evaluated using Mac Pymol. In all cases, the lowest energy scores were identical
for several of the predicted models, suggesting an optimal folding energy of the
chosen model.
Passive immunization. Female BALB/cAnNHsd mice (age, 10 weeks or 12
months; Harlan, Indianapolis, IN) were anesthetized with a ketamine (1.3 mg/
mouse)–xylazine (0.38 mg/mouse) mixture administered intraperitoneally in a
50-l volume. Each mouse was intranasally inoculated with 106 PFU (icUrbani,
icGZ02, or icHC/SZ/61/03) or 105 PFU (icMA15) of icSARS-CoV in a 50-l
volume.
In experiments 1 and 2 (Table 1), 12-month-old mice were injected intraperi-
toneally with 25 or 250 g of various human MAbs (D2.2, S109.8, S227.14, or
S230.15) in a 400-l volume at 1 day prior to intranasal inoculation with 106 PFU
of the different icSARS-CoV strains (n 	 3 per MAb per virus per time point).
In experiment 3 (Table 1), 12-month-old mice were injected with a cocktail of
S109.8, S227.14, and S230.15 (containing 83 g of each MAb) with a total
concentration of 250 g MAb in 400 l at 1 day prior to inoculation with 106
PFU icHC/SZ/61/03 (n 	 3 per time point). In experiment 4 (Table 1), 10-week-
old mice were injected with 250 g of S230.15 at 1 day prior to inoculation with
106 PFU of icHC/SZ/61/03 (n 	 4). In experiment 5 (Table 1), 10-week-old mice
were injected with 25 g of D2.2, S109.8, S227.14, or S230.15 at 1 day prior to
inoculation with 105 PFU of icMA15 (n 	 3 per MAb per time point). In
experiment 6 (Table 1), 12-month-old mice were injected with 250 g of S230.15
at 1, 0, 1, 2, or 3 days after inoculation with 106 PFU icGZ02 (n 	 5 per
treatment per time point). All animals were weighed daily, and at 2, 4, or 5 days
postinfection, serum and lung samples were removed and frozen at 70°C for
later determination of viral titers by plaque assays. Lung tissue was also removed
for histological examination on day 4 or 5 depending on whether animals had to
be euthanized due to 20% weight loss.
All mice were housed under sterile conditions in individually ventilated Seal-
safe cages using the SlimLine system (Tecniplast, Exton, PA). Experimental
protocols were reviewed and approved by the Institutional Animal Care and Use
Committee at the University of North Carolina, Chapel Hill.
Virus titers in lung samples. Tissue samples were weighed and homogenized
in 5 equivalent volumes of PBS to generate a 20% solution. The solution was
centrifuged at 13,000 rpm under aerosol containment in a tabletop centrifuge for
5 min; the clarified supernatant was serially diluted in PBS; and 200-l volumes
of the dilutions were placed on monolayers of Vero cells in 6-well plates. Fol-
lowing a 1-h incubation at 37°C, cells were overlaid with a medium containing
0.8% agarose. Two days later, plates were stained with neutral red, and plaques
were counted.
Histology. All tissues were fixed in 4% paraformaldehyde in PBS (pH 7.4)
prior to being submitted to the Histopathology Core Facility (University of
Norrth Carolina, Chapel Hill) for paraffin embedding, sectioning at a 5-m
thickness, and hematoxylin and eosin staining. Lung pathology was evaluated in
a blinded manner.
RESULTS
Identification of cross-neutralizing MAbs. A panel of 23
human MAbs was tested for neutralizing activity against one or
multiple icSARS-CoV bearing spike variants from the late,
middle, early, and zoonotic phases of the epidemic. The panel
includes a number of new MAbs (S228.11, S222.1, S237.1,
S223.4, S225.12, S226.10, S231.19, S232.17, S234.6, S227.14,
S230.15, S110.4, and S111.7) that were not described in the
initial study (47) and that, except for S110.4 and S111.7, were
all isolated at a late time point after infection with SARS-CoV
(2 years). All MAbs efficiently neutralized the late-phase
icUrbani isolate (Table 2), which was homologous to the strain
isolated from the patient used to produce the MAbs (50).
Interestingly, in testing of the MAbs against the middle-phase,
early-phase, and zoonotic isolates, six distinct neutralization
patterns were identified (Table 2). Two unique group I MAbs
that specifically neutralized the homologous late-phase isolate,
icUrbani, were identified. Two MAbs that neutralized the ho-
mologous icUrbani strain about 10-fold more efficiently than
the middle-phase isolate, icCUHK-W1, comprise group II.
Group III contains five MAbs that were about 50-fold more
efficient at neutralizing the icUrbani reference strain than the
group I antibodies. These antibodies were extremely efficient
at neutralizing the human late-, middle-, and early-phase iso-
lates (n 	 5), but not the zoonotic isolates, at all concentra-
tions tested (8 ng/ml to 16 g/ml). Group IV consists of eight
MAbs that were extremely efficient at neutralizing the human
isolates as well as the palm civet isolate icHC/SZ/61/03. It is
likely that two or more neutralizing epitopes exist within this
cluster, since some MAbs were equally efficient at neutralizing
human and zoonotic isolates (e.g., MAbs 225.12, 226.10, and
234.6) while others required a 10-fold-higher concentration to
neutralize the civet isolate (e.g., MAbs 218.9, 231.19, and
232.17). The group V cluster consists of two MAbs that neu-
tralized variable subsets of the human and zoonotic strains, but
only at high concentrations. Finally, group VI consists of four
MAbs that neutralized all human and zoonotic strains avail-
able within our panel of variant SARS-CoV spike variants.
Because of the different concentrations of antibody needed to
neutralize isolates for each MAb in group VI, we suspected
that at least two or three different panspecific neutralizing
epitopes likely exist in the SARS-CoV S glycoprotein.
TABLE 1. Experimental design of passive immunization
studies on mice
Expt
Amt of
MAb
(g)
MAb(s) Day(s) ofvaccination
Challenge
virus(es)
Age
of
mice
1 25 D2.2, S109.8, S227.14,
S230.15
1 icUrbani, icGZ02,
icHC/SZ/61/03
12 mo
2 250 D2.2, S109.8, S227.14,
S230.15
1 icUrbani, icGZ02,
icHC/SZ/61/03
12 mo
3 250 S109.8  S227.14 
S230.15 (cocktail)
1 icHC/SZ/61/03 12 mo
4 250 S230.15 1 icHC/SZ/61/03 10 wk
5 25 D2.2, S109.8, S227.14,
S230.15
1 icMA15 10 wk
6 250 S230.15 1, 0, 1, 2, 3 GZ02 12 mo
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Identification of MAbs that inhibit the binding of the SARS-
CoV S glycoprotein to ACE2. To identify the MAbs that di-
rectly inhibit the binding of SARS-CoV to its cellular receptor,
ACE2, as a mechanism of neutralization, we assessed the ca-
pacity of the MAb panel described above to inhibit the binding
of the SARS-CoV S1 domain to human ACE2 expressed on
the surfaces of transfected murine DBT cells. The antibody
activity is expressed as the concentration that blocks 50% of
spike binding to ACE2 and as maximum-inhibition values (Ta-
ble 2). Most of the antibodies completely inhibited binding,
although with different potencies (Table 2; see, for example,
S230.15 and S3.1). Of note, some antibodies only partially
inhibited the binding of the spike protein, even when tested at
the highest concentrations (Table 2; see, for example, S124.5
and S109.8). Not surprisingly, a significant correlation was ob-
served between neutralization titers and inhibition titers for
the binding of the SARS-CoV S glycoprotein to ACE2 (r2 	
0.344; P 	 0.002). However, a few antibodies, such as S3.1 and
S127.6, showed a high virus neutralization capacity in spite of
a low capacity to interfere with the binding of the spike protein
to its receptor (Table 2).
Sequence analysis of virus neutralization. By using a panel
of S glycoprotein variants, the amino acid changes associated
with loss of neutralization can be identified. To identify possi-
ble locations of neutralizing epitopes recognized by these
MAbs, the neutralization groups were annotated in accordance
with the amino acid sequence variations noted in the different
S glycoproteins used in this study (Fig. 1A). Interestingly,
group I MAbs S132 and S228.11 uniquely neutralized
icUrbani, which differs at positions G77D and I244T in the S1
domain from the resistant middle-phase isolate icCUHK-W1
(Fig. 1A). Although the mechanism is unclear, these two
unique residues in icUrbani, either individually or in concert,
result in either (i) microvariation within overlapping epitopes,
(ii) changes in conformational epitopes, or (iii) mutations that
alter the surface topology of a group I epitope. In accordance
with these findings, four amino acid differences (Fig. 1A) were
observed between the middle-phase icCUHK-W1 and the
early-phase icGZ02 S glycoprotein. The fact that group II
antibodies efficiently inhibit RBD binding to ACE2 implies
that the critical residues are likely those residing within the
RBD (G311R and K344R). In contrast, the mutations that
TABLE 2. Characterization of a panel of human MAbs for their capacities to neutralize human and zoonotic SARS-CoV strains and to
inhibit the binding of the SARS-CoV S glycoprotein to human ACE2a
Group MAb
50% Neutralization titer (ng/ml)b for the indicated virus
Inhibition of SARS-
CoV S binding to
ACE-2c
Human Zoonotic Neutralization escape variant
%
Inhibition
IC50
(ng/ml)Late
(Urbani)
Middle
(CUHK-W1)
Early
(GZ02)
Palm civet
(HC/SZ/61/03)
Raccoon
dog
(A031G)
GZ02-109-1 GZ02-109-2 GZ02-230
I S132 1,984     NT NT NT 60 2,570
S228.11 196     NT NT NT 97 598
II S111.7 154 1,232    NT NT NT 96 1,208
S224.17 194 1,552    NT NT NT 98 297
III S3.1 45 180 720   NT NT NT 96 868
S127.6 65 259 518   NT NT NT 97 876
S217.4 30 59 118   NT NT NT 99 114
S222.1 51 202 808   NT NT NT 98 98
S237.1 8 67 34   NT NT NT 97 66
IV S110.4 81 322 644 1,288  NT NT NT 99 476
S218.9 31 123 246 1,968  NT NT NT 101 280
S223.4 20 79 158 316  NT NT NT 99 112
S225.12 9 18 72 72  NT NT NT 99 68
S226.10 23 90 360 180  NT NT NT 99 92
S231.19 18 71 141 2,256  NT NT NT 99 120
S232.17 90 180 360 2,880  NT NT NT 100 95
S234.6 64 2,032 254 254  NT NT NT 100 142
V S124.5 1,400 5,600  1,120 5,600 NT NT NT 56 4,700
S219.2 248 992   496 NT NT NT 44 3,000
VI S109.8 424 848 3,392 424 53   3,300 85 525
S215.17 25 100 200 400 3,200 NT NT NT 98 200
S227.14 19 77 153 306 77 150 150 150 100 126
S230.15 20 40 160 160 80 155 155  99 84
a A panel of 23 human mAbs was tested for their capacities to neutralize recombina NT SARS-CoV S glycoprotein variants (Urbani, CUHK-W1, GZ02,
HC/SZ/61/03, and A031G) and neutralization escape variants (GZ02-109-1, GZ02-109-2, and GZ02-230). MAbs are ranked in six groups according to their capacities
to neutralize different SARS-CoV S glycoprotein variants.
b MAb concentration at which 50% of the viruses are neutralized. , no neutralizing titer detected at 10 g/ml; NT, not tested.
c The percentage of maximal inhibition by each MAb of SARS-CoV S glycoprotein binding to human ACE2 expressed by murine DBT cells is shown, along with
the concentration at which 50% of the binding is blocked (IC50).
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influence the binding and activity of the group III MAbs are
the most complex and are influenced by 1 or more of 15 amino
acid differences between the early-phase icGZ02 and the zoo-
notic palm civet icHC/SZ/61/03 isolate. These amino acids are
scattered throughout the S1, RBD, and S2 domains (Fig. 1A);
however, all group III antibodies efficiently inhibit RBD bind-
ing to ACE2, suggesting that the critical residues are those
residing within the RBD. The RBD residues include F360,
L472, N479, and D480. The neutralization activity of the group
IV MAb cluster is heavily influenced by two amino acid dif-
ferences between the zoonotic strains icHC/SZ/61/03 and
icA031G (raccoon dog isolate), located in the RBD (P462S) or
in the S2 domain (E821Q) of the S glycoprotein (Fig. 1A).
Again, the efficient inhibition of the binding of the RBD to
ACE2 suggests that P462S is the critical residue. The recogni-
tion domain of the group VI broad-spectrum antibodies must
be conserved across the panel, and the location is unclear,
although S230.15 has previously been shown by competition
ELISA to bind to the RBD in the S glycoprotein (57) and all
the group VI MAbs have been shown to interfere with binding
to ACE2 expressed on the surface of the cell membrane.
Competition studies for the definition of epitopes recog-
nized by broadly neutralizing MAbs. Our data suggest that the
majority of the human MAbs recognize epitopes differentially
defined by a few mutations within the RBD. Competition stud-
ies were performed to determine the spatial proximity of each
of the conformational epitopes recognized by the three most
broadly neutralizing MAbs to the other epitopes on the SARS-
FIG. 1. Mapping of neutralizing epitopes on the SARS-CoV S glycoprotein recognized by human MAbs through sequence analysis and
cross-competition studies. (A) Sequence analysis of the amino acid differences in the SARS-CoV S glycoproteins of zoonotic and human epidemic
isolates and their associations with binding to neutralizing human MAbs. The graphic representation of the SARS-CoV S glycoprotein shows the
locations of the variant amino acids in the RBD and heptad repeat 2 (HR2). Three neutralizing domains have previously been identified by using
murine MAbs and antisera targeting the S glycoprotein. Domain I is localized in the N terminus of the S1 domain between amino acid residues
130 and 150; however, the mechanism by which these antibodies neutralize infectivity remains unknown (10). Domain II includes the RBD
(residues 318 to 510), where antibodies likely block binding to the SARS-CoV receptor ACE2, based on studies describing the crystal structures
of two different neutralizing MAbs in complex with the RBD (13, 15, 32). Finally, domain III includes HR2 (residues 1143 to 1157) and is likely
neutralized by disturbing the interaction between HR2 and HR1, thereby abolishing fusion activity (20). Amino acids associated with recognition
by MAbs are color coded as follows: blue, group I MAbs; red, group II MAbs; green, group III MAbs; yellow, group IV MAbs. MAb groups are
shown in Table 2 and defined in the text under “Identification of cross-neutralizing MAbs.” (B) Cross-competition of MAbs binding to the
SARS-CoV S glycoprotein. Shown are the percentages of inhibition of the binding of 3 biotinylated MAbs (S109.8, S227.14, and S230.15;
concentration, 0.1 g/ml) to the recombinant SARS-CoV S glycoprotein by a panel of 23 unlabeled competing MAbs (at a saturating concentration
[5 g/ml]) belonging to groups I through VI. Error bars, standard deviations from triplicates. ctr, control.
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CoV S glycoprotein. MAbs S109.8, S227.14, and S230.15 were
purified, biotinylated, and tested for their capacities to bind the
SARS-CoV spike protein in the presence of other, unlabeled
MAbs. In interpreting competition results, it should be taken
into account that when two epitopes overlap, or when the areas
covered by the arms of the two MAbs overlap, competition
should be almost complete. Weak inhibitory or enhancing ef-
fects may simply reflect a decrease in affinity owing to steric or
allosteric effects (28, 49). The two most potent cross-neutral-
izing MAbs, S227.14 and S230.15, compete with each other
(Fig. 1B) and with all other MAbs except the group I MAbs
(S132 and S228.11), the group V MAbs (S124.5 and S219.2),
MAb S3.1 (group III), and MAb S109.8 (group VI). MAb
S230.15 has a higher affinity than MAb S227.14, as evidenced
by the fact that MAb S230.15 competes with MAb S227.14 at
a concentration 16-fold lower than that required for MAb
S227.14 to compete with S230.15 (46 ng/ml and 738 ng/ml,
respectively). MAb S109.8 did not compete with any of the
MAbs, although limited inhibition was seen with S127.6 (61%
[Fig. 1B]).
Escape mutant analysis of broadly neutralizing MAbs. Iso-
late icGZ02, which produces lethal infections in aged but not
young mice (37), was used to generate antibody neutralization
escape mutants by incubating and culturing high titers of virus
in the presence of MAbs S109.8, S227.14, and S230.15. After 3
passages, the resulting viruses were plaque purified and tested
for neutralization efficacy. The S109.8 escape mutant of
icGZ02, in contrast to wild-type icGZ02, was no longer neu-
tralized by S109.8, even at antibody concentrations exceeding
20 g/ml (Table 2). However, both S227.14 and S230.15 were
as effective at neutralizing the S109.8 escape mutant of icGZ02
as they were at neutralizing the wild-type virus.
Similarly, the S230.15 escape mutant was no longer neutral-
ized by S230.15 but was still effectively neutralized by both
MAbs S109.8 and S227.14 (Table 2). This finding was partic-
ularly interesting because S227.14 had been shown to compete
with S230.15 for binding to the RBD; it confirmed that S227.14
and S230.15 recognize overlapping but distinct epitopes. In
addition, no escape mutant of MAb S227.14 was isolated in two
independent experiments, suggesting that the epitope recog-
nized by MAb S227.14 may be less susceptible to sequence
variation, possibly due to the presence of receptor contact
residues within its epitope or other steric constraints that re-
duce the likelihood of escape mutations evolving in this region.
A minimum of five plaques of each escape variant were
sequenced in order to identify mutations associated with the
antibody escape phenotype. All five plaques of the S230.15
escape mutant contained a single amino acid change at loca-
tion L443R. Four out of six plaques of the S109.8 escape
mutants contained a single amino acid change at T332I, while
two plaques contained a single amino acid change in an adja-
cent residue at position K333N.
Structural modeling of cross-neutralizing epitopes. Re-
cently, the structure of the SARS-CoV RBD complexed with
its receptor, ACE2, was resolved, allowing for structural mod-
eling of amino acid changes within the RBD (21). Both muta-
tions observed with the S109.8 escape mutants flank the side of
the RBD in a loop that is not in direct contact with the recep-
tor, ACE2 (Fig. 2A). The T332I change results in a protrusion
from the surface due to the additional CH3 group, and the
residue becomes strongly hydrophobic. Alternatively, the
amino acid change from Lys to Asn at position 333 removes a
positive charge. Both mutations clearly affect binding of MAb
S109.8. The mechanism of neutralization by S109.8 is unknown
but may either involve structural changes to the RBD after
binding or provide a steric hindrance that antagonizes receptor
binding in some unspecified manner.
Structural analysis of the S230.15 escape mutant showed that
subtle remodeling of the receptor binding pocket did not im-
pact the binding of ACE2. The selected arginine mutation
residue is likely forced into the binding pocket by surrounding
positively charged amino acids. At this site, a binding pocket
exists that can accommodate the larger side chain without
disrupting interface site interactions (Fig. 2B). However, the
presence of arginine at this position likely abolishes the bind-
ing of S230.15. These data support the hypothesis that MAb
S230.15 neutralizes SARS-CoV by directly blocking the inter-
action with its receptor, ACE2.
The combined results from the sequence analysis, competi-
tion assays, and escape mutant analysis allowed us to identify
the amino acids that were associated with the neutralization
efficacy of the three different cross-neutralizing MAbs. By
mapping the locations of these amino acids onto the crystal
structure of the SARS-CoV strain Urbani RBD bound to
ACE2, putative locations of the cross-neutralizing epitopes
could be identified (Fig. 2C). MAb S230.15 likely recognizes an
epitope that includes aa 443, as shown by escape variant anal-
ysis, as well as aa 487, as shown by reduced in vitro neutral-
ization of an SZ16 spike variant with a T487S change (57). The
epitope recognized by MAb S227.14 partially overlaps with
recognized by S230.15 but is not affected by the L443R change
identified in the S230.15 escape mutant. Finally, the epitope
recognized by S109.8 includes aa 332 and 333, as shown by
escape mutant analysis.
Use of human MAbs for prophylaxis in senescent-animal
models. Our data strongly support the hypothesis that MAbs
S109.8, S227.14, and S230.15 are potent cross-neutralizing hu-
man MAbs that recognize the RBD of the SARS-CoV S gly-
coprotein. S109.8 recognizes a unique epitope distinct from the
receptor binding site, while S227.14 and S230.15 recognize
partially overlapping epitopes that coincide with the receptor
binding site. These broad-spectrum neutralizing MAbs were
therefore tested for their abilities to protect against lethal
homologous and heterologous SARS-CoV challenges in vivo.
Previous studies with a murine model of acute nonlethal chal-
lenge indicated that 200 g of MAb S230.15 was protective
against SARS-CoV infection, but MAb prophylaxis had not
been studied with aged mice (57). SARS-CoV typically pro-
duces severe disease in senescent populations, requiring a pro-
phylactic approach that would protect both young and older
populations. We have previously shown that infection of 12-
month-old BALB/cBy mice with 105 PFU of icGZ02 or icHC/
SZ/61/03 resulted in death or 20% weight loss by day 4 or 5
(37), whereas mice infected with 105 PFU of icUrbani lost only
10% of their weight. Interestingly, by increasing the challenge
titer 10-fold to 106 PFU, the typically mild pathogenic pheno-
type of icUrbani was increased: weight loss for 1-year-old
BALB/cAnNHsd mice approached 20% by day 4 or 5 (Fig. 3A,
D2.2).
Twelve-month-old BALB/c mice that received 25 g of
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FIG. 2. Locations of neutralization escape variant mutations and effects on the structure of the SARS-CoV RBD. (A and B) The S109.8 escape
variant mutations T332I and K333N (A) and the S230.15 escape variant mutation L443R (B) were mapped onto the structure of the SARS-CoV
RBD. The changed amino acid residues are shown in red. (C) The locations of all the important amino acid residues associated with the cross
neutralizing MAbs are highlighted in the SARS-CoV RBD. Yellow, amino acid residues associated with S109.8; red, amino acid residues associated
with S227.14; purple, amino acid residues associated with S230.15.
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MAb S227.14 or S230.15 intraperitoneally 24 h prior to infec-
tion were protected against significant weight loss (P 
 0.01 by
the t test) and had reduced viral titers in their lungs on days 2
and 5, approaching reductions of 1.5 to 2 and 2 to 4 log units,
respectively, following challenge with icUrbani or icGZ02 (Fig.
3A, B, D, and E). Animals challenged with icHC/SZ/61/03 that
had received 25 g of MAb S227.14 or S230.15 were less
efficiently protected but displayed significant reductions in
weight loss, which approached 12% of weight by day 4 (P 

0.01 by the t test) (Fig. 3C). In addition, all animals receiving
MAb S227.14 or S230.15 recovered by day 5. In contrast, an-
imals that received the irrelevant MAb D2.2 or MAb S109.8
were not protected against weight loss after challenge with
homologous or heterologous icSARS-CoV; all these animals
lost 20% of their weight by day 4 postinfection (Fig. 3C). In
addition, virus titers remained high in mice that received
S109.8 and were challenged with icUrbani or icGZ02, as well
as in all of the BALB/c mice challenged with icHC/SZ/61/03,
demonstrating that this antibody was less efficient at protecting
animals from lethal infection, especially at low doses (Fig. 3D
and E).
We used a very high dose of the challenge inocula to provide
the most stringent test for MAb effectiveness, so it was not sur-
prising that a 25-g MAb dose produced variable results with
some MAbs and challenge viruses. To determine whether a high
dose of MAb would enhance prophylaxis against clinical disease
and death, 12-month-old BALB/c mice were dosed with 250g of
MAb D2.2, S109.8, S227.14, or S230.15 1 day prior to infection.
As expected, animals that received S227.14 or S230.15 were pro-
tected against significant weight loss after challenge with icUr-
bani, icGZ02, or icHC/SZ/61/03 (P
 0.01 by the t test) (Fig. 4A,
B, and C). Importantly, the 10-fold-increased dose of S109.8 was
completely protective; animals did not lose significant weight after
challenge with icUrbani or icGZ02 and were partially protected
against icHC/SZ/61/03 clinical disease, losing significantly less
weight (10% of weight by day 3; P 
 0.01 by the t test) than
controls relative to icUrbani-challenged animals (Fig. 4A, B, and
C). Importantly, animals recovered by day 5 postinfection, dem-
onstrating that the antibody protected against severe clinical dis-
ease and death (Fig. 4C). On days 2 and 5 following challenge
with icUrbani or icGZ02, no virus could be detected in the lungs
of animals that had received S227.14 or S230.15 (P 
 0.01 by
analysis of variance [ANOVA]) (Fig. 4D and E), but interestingly,
only1- and2-log-unit reductions were observed, respectively,
after challenge with icHC/SZ/61/03 (P
 0.05 by ANOVA). In the
lungs of BALB/c mice that received S109.8, only limited reduc-
FIG. 3. Prophylactic treatment of lethal SARS-CoV infection in 12-month-old BALB/c mice with 25 g of cross-neutralizing MAbs. (A to C)
Body weights of mice infected with icUrbani (A), icGZ02 (B), or icHC/SZ/61/03 (C) were measured daily after passive transfer of 25 g of MAb
S109.8 (), S227.14 (E), S230.15 (), or D2.2 (). (D and E) Lung tissues were harvested from infected mice on day 2 (D) and day 5
(E) postinfection and were assayed for infectious virus. Error bars, standard deviations (n 	 3).
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tions in viral titers were observed (1 log unit) on day 2 after
challenge with icUrbani or icGZ02 (P 
 0.01 by ANOVA), and
no reduction was observed in icHC/SZ/61/03 titers. However, no
viral replication could be detected in the lungs of mice infected
with any of the viruses at day 5 postinfection, demonstrating an
enhanced rate of clearance over time (Fig. 4E).
Broad-spectrum MAb cocktail. Previous studies have sug-
gested that cocktails of neutralizing antibodies may enhance
protection against virus infection (46). Since single-MAb treat-
ment regimens did not protect 12-month-old BALB/c mice
against virus replication after challenge with the heterologous
strain icHC/SZ/61/03, animals were dosed with a cocktail of
equal amounts of MAbs S109.8, S227.14, and S230.15 (83 g of
each MAb) at a final concentration of 250 g in order to test
the hypothesis that multiple MAbs recognizing distinct neu-
tralizing epitopes may increase immunization efficacy. Animals
that received the cocktail were completely protected against
weight loss following infection with icHC/SZ/61/03 (P 
 0.01
by the t test) (Fig. 4C). In addition, viral titers in the lungs on
day 2 postchallenge (Fig. 4D) were similar to those for animals
that received MAb S227.14 or S230.15 alone, but about 2 log
units lower than those for animals that received MAb S109.8
alone. As with mice treated with a single MAb, no virus could
be detected at 5 days postinfection (Fig. 4E).
Protection of young mice from lethal challenge. MAb
S230.15 has recently been shown to protect young mice against
replication of recombinant SARS-CoV bearing another palm
civet S glycoprotein (SZ16) (37). Surprisingly, the same MAb
did not completely protect 12-month-old BALB/c mice against
lethal challenge with another civet virus variant, icHC/SZ/61/
03. To determine whether the failure of the passive immuni-
zation against icHC/SZ/61/03 was specific for aged mice, an
identical passive immunization experiment was performed on
10-week-old BALB/c mice. As shown previously for 8-week-old
mice (37), young mice challenged with icHC/SZ/61/03 did not
lose weight or display other clinical disease symptoms (data not
shown), and virus titers in young and old mice were compara-
ble. Interestingly, only one out of three mice that received a
250-g dose of S230.15 had detectable viral titers (7  106
PFU/g), demonstrating enhanced functional activity in younger
animals. In control animals, icHC/SZ/61/03 replicates to equiv-
alent titers at day 2 postinfection, suggesting that passive an-
tibody transfer may be less efficient at protecting the lungs of
immunosenescent populations.
FIG. 4. Prophylactic treatment of lethal SARS-CoV infections in 12-month-old BALB/c mice with 250 g of cross-neutralizing MAbs. (A to
C) Body weights of mice infected with icUrbani (A), icGZ02 (B), or icHC/SZ/61/03 (C) were measured daily after passive transfer of MAbs S109.8
(), S227.14 (E), S230.15 (), and D2.2 (), all at 250 g/mouse, given alone or as a 1:1:1 cocktail of the three neutralizing MAbs (‚). (D and
E) Lung tissues were harvested from infected mice on day 2 (D) and day 5 (E) postinfection and were assayed for infectious virus. Error bars,
standard deviations (n 	 3).
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The recent development of a mouse-adapted SARS-CoV
variant (icMA15) (33) allowed us to test MAb effectiveness
against a homologous lethal challenge virus in young mice. The
MA15 virus has a single mouse-adapted change in the S gly-
coprotein at residue Y436H. Ten-week-old BALB/c mice that
received 25 g of S227.14 were significantly and completely
protected against weight loss after challenge with icMA15 (Fig.
5A). Animals that received either S230.15 or S109.8 all had
significant weight loss starting by day 3 or 2 postinfection,
respectively (P 
 0.01 by the t test), with a maximum of 15%,
but eventually leveled out by day 4 (Fig. 5A). Virus titers in the
lungs of animals that received S227.14 were lower on day 2
than those for animals that received either S230.15, S109.8, or
the D2.2 control (Fig. 5B). Interestingly, on day 4, no virus
could be detected in the lungs of animals treated with S227.14
(Fig. 5C).
Postinfection treatment of lethal challenge. Given the possi-
bility of lethal infection and community spread, antibody prophy-
laxis following SARS-CoV exposure is an important public health
consideration, especially for laboratory personnel. Therefore, one
of the most efficient cross-neutralizing MAbs, S230.15, was used
prophylactically at a dose of 250 g at different times after expo-
sure with icGZ02 in an aged-mouse infection model. Complete
protection from weight loss was observed when 12-month-old
BALB/c mice were immunized 1 day prior to challenge (Fig. 6A).
Mice immunized at the time of infection lost up to 10% of their
weight by day 2 postchallenge (P 
 0.01 by the t test) but recov-
ered by day 3. Treatment of BALB/c mice at 1, 2, or 3 days
postchallenge did not protect against weight loss, suggesting a
narrow window of prophylactic activity in the mouse model of
acute lethal challenge (Fig. 6A).
Virus titers in the lungs were examined on days 2 and 4. By
day 2 postchallenge, complete protection against virus replica-
tion in the lungs of BALB/c mice treated with the MAb 1 day
prior to challenge was observed (P 
 0.01 by ANOVA) (Fig.
6B). In contrast, a 5-log-unit reduction in virus titers was ob-
served when mice were treated on the day of challenge (de-
tectable virus in only one out of four animals; P 
 0.01 by
ANOVA). Consistent with the development of severe clinical
disease, no reduction in viral titers was observed when mice
were treated 1 day postchallenge (Fig. 6B). By day 4 postchal-
lenge, virus was no longer detectable in the lungs of mice
treated 1 day prior to challenge, on the day of challenge, or 2
or 3 days postchallenge (P 
 0.01 by ANOVA), and virus was
FIG. 5. Prophylactic treatment of lethal SARS-CoV infections in
10-week-old BALB/c mice with 25 g of cross-neutralizing MAbs.
(A) Body weights of mice infected with MA15 were measured daily
after passive transfer of 25 g of MAb S109.8 (), S227.14 (E),
S230.15 (), or D2.2 (). (B) Lung tissues of mice infected with
MA15 or icHC/SZ/61/03 were harvested on day 2 postinfection and
assayed for infectious virus. (C) Lung tissues of mice infected with
MA15 were harvested on day 4 postinfection and assayed for infectious
virus. Error bars, standard deviations (n 	 3). *, only one animal out
of three had detectable virus titers.
FIG. 6. Postinfection treatment of 12-month-old BALB/c mice infected with SARS-CoV. (A) Body weights of mice infected with GZ02 were
measured daily after passive transfer of 250 g of MAb S230.15 at day 1 (), day 0 (E), or day 1 (), 2 (), or 3(‚) postinfection. (B) Lung
tissues of mice infected with GZ02 were harvested on days 2 and 4 postinfection and were assayed for infectious virus. Error bars, standard
deviations (n 	 5). *, only one animal out of five had detectable virus titers.
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detectable only in one out of five BALB/c mice treated with the
MAb on day 1 postchallenge (Fig. 6B).
These data suggest that the lethal course of SARS-CoV
infection in the mouse model may well be set within the first
24 h postinfection, since this MAb was not capable of reversing
the severity of clinical disease.
Pathological findings. The recapitulation in BALB/c mice of
the age-related pathology observed in acute cases of SARS-
CoV infection in humans (37) provides us with a third measure
of protection along with morbidity and viral titers. Although
there was some animal-to-animal variation, in general 12-
month-old BALB/c mice that received the control MAb D2.2
showed evidence of bronchiolitis with epithelial cell exfolia-
tion, virus-induced peribronchiolar inflammation, diffuse acute
alveolitis, and numerous hyaline membranes in the alveolar
airspaces after infection with icUrbani (Fig. 7A), icGZ02 (Fig.
7C), or icHC/SZ/61/03 (Fig. 7E). Animals that received 250 g
of either MAb 230.15 (Fig. 7B, D, and F) or a cocktail of MAbs
FIG. 7. Light photographs of preterminal bronchioles (PB) in the lungs of 12-month-old BALB/c mice that had received 250 g of a human
MAb prior to SARS-CoV infection and were sacrificed 5 days postinoculation. Virus-induced peribronchiolar inflammation (solid arrows) is
evident in mice treated with the control MAb D2.2 and infected with icUrbani (A), icGZ02 (C), or icHC/SZ/61/03 (E). Numerous hyaline
membranes (dashed arrows) are present in the alveolar airspaces of mice treated with the control MAb. No inflammation or hyaline membrane
formation can be observed in mice treated with 250 g of S230.15 and subsequently infected with icUrbani (B), icGZ02 (D), or icHC/SZ/61/03
(F). AL, alveoli; AD, alveolar ducts; BV, blood vessels. Tissues were stained with hematoxylin and eosin. Magnification, 100.
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S109.8, S227.14, and S230.15 (data not shown) before infection
showed marked decreases in bronchiolitis, exfoliation, and al-
veolar inflammation, and hyaline membrane formation was
absent. No clear decrease in alveolar inflammation or bronchi-
olitis was observed when animals received 25 g of either MAb
230.15 or the cocktail; however, animals were protected against
hyaline membrane formation (data not shown). Finally, in
agreement with the morbidity data, mice showed clear reduc-
tions in pathological changes only when they were treated with
the MAb 1 day prior to the day of infection (Fig. 7D) or on the
day of infection (Fig. 8A), not when they were treated on day
1, 2, or 3 postinfection (Fig. 8B, C, and D, respectively). No
evidence of enhanced disease or pathology was observed with
any of the MAbs or any of the challenge viruses.
DISCUSSION
SARS-CoV is a newly emergent human respiratory patho-
gen that caused a major outbreak in community settings
around the world in 2002 to 2003. Several laboratory-acquired
cases have been reported with subsequent spread of the dis-
ease into communities, resulting in additional outbreaks in
2003 to 2004 (25, 31). Since these epidemics, no human cases
have been reported, and epidemic human strains are believed
to be extinct. However, several SARS-CoV strains have been
sequenced from possible zoonotic reservoirs, including palm
civets, raccoon dogs, and bats, and new human strains will
likely evolve from these reservoirs (11, 23). In support of this
hypothesis, we have shown that many of these animal strains
encode an S glycoprotein that can utilize human ACE2 for
docking and entry (37). Additionally, the SARS-CoV infec-
tions involving researchers underscore the need for medical
countermeasures for postexposure prophylaxis. Therefore,
protection against zoonotic and early human-to-human trans-
mission, especially in more vulnerable elderly populations,
should receive high priority (3, 5, 36).
The goal of this study was to identify and characterize cross-
neutralizing human MAbs that efficiently neutralize an exten-
sive panel of variant SARS-CoV isolates bearing S glycopro-
teins from both the human and the zoonotic phases of the
epidemic (37). For the first time, we evaluated the use of
human MAbs in the prevention and treatment of lethal ho-
mologous and heterologous SARS-CoV infections in murine
models. Uniquely, this study not only carefully mapped the
cross-reactive neutralization effectiveness of a large panel of
human MAbs against human and zoonotic isolates but also
identified at least three MAbs that recognize unique epitopes
and neutralize all SARS-CoV isolates tested in vitro and in
FIG. 8. Light photographs of preterminal bronchioles (PB) and terminal bronchioles (TB) in the lungs of 12-month-old BALB/c mice that
received 250 g of a human MAb after infection with SARS-CoV and were sacrificed 5 days postinoculation. (A) No inflammation or hyaline
membrane formation can be observed in mice treated with 250 g of S230.15 on the day of infection with icGZ02. (B through D) Increasing-virus
induced peribronchiolar inflammation (solid arrows) is evident in mice treated with 250 g of MAb S230.15 at day 1 (B), 2 (C), or 3
(D) postinfection. AL, alveoli; AD, alveolar ducts; BV, blood vessels. Tissues were stained with hematoxylin and eosin. Magnification, 100.
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vivo. A similar strategy has recently been used to identify
cross-reactive protective human MAbs against influenza virus
H5N1 (41).
Several studies have shown that the generation of neutral-
izing antibodies against SARS-CoV is a major component of
protective immunity (47, 48). A few studies have focused on
evaluating the cross-neutralizing potential of human and mu-
rine antibodies and have measured cross-neutralization in-
dexes using a small number of pseudotyped viruses bearing S
glycoproteins from SARS-CoV isolates throughout the epi-
demic (12, 56). These studies have demonstrated mixed results
ranging from no cross-neutralization to enhanced infection
and even robust cross-neutralization, complicating the inter-
pretation of data.
Given the variable responses reported with pseudotyped vi-
ruses (30, 55), we used an isogenic panel of recombinant
SARS-CoVs bearing variant human epidemic and zoonotic S
glycoproteins to evaluate the role of S glycoprotein heteroge-
neity in neutralization by MAbs (37). Using this panel of vi-
ruses, we identified 23 human MAbs that effectively neutral-
ized one or multiple SARS-CoV S isolates, dividing the
antibodies into six distinct neutralizing categories. More im-
portantly, we identified four MAbs that efficiently neutralize
both human and zoonotic SARS-CoV isolates. MAb S230.15
has recently been shown to have cross-neutralizing in vitro and
in vivo activities against GD03-S and SZ16-K479N recombi-
nant viruses (57); however, we expanded on these studies to
include several more MAbs and three more SARS-CoV spike
isolates as well as mapping of the putative epitopes.
In agreement with previous studies, sequence analysis, com-
petition studies, and inhibition of SARS-CoV S binding to
ACE2 showed that the majority of our panel of MAbs recog-
nized epitopes within the RBD, with the exception of two
MAbs (S132 and S228.11, constituting group I) that likely
recognize epitopes in the N terminus of the S1 domain. The
majority of the human MAbs (groups III and IV) likely rec-
ognize a set of overlapping conformational epitopes, since
reactivity was lost by denaturation of the antigen, as seen with
the hepatitis B virus surface antigen (38).
At least three of the cross-neutralizing MAbs (S109.8,
S230.15, and S227.14) were mapped within the RBD. Since
S230.15 and S227.14 compete with S215.17, all the cross-neu-
tralizing antibodies likely map in the RBD. The epitope of
MAb S230.15 likely overlaps with the epitopes that were rec-
ognized by 80R and m396, since at least one amino acid (aa
487) was identified as an important residue both for S230.15
and for 80R and m396 (15, 32, 43). MAb S227.14 was shown to
recognize an epitope that partially overlapped with the S230.15
epitope but is likely distinct from the 80R and m396 epitopes.
Recognition of partially overlapping but distinct epitopes has
also been reported for other viruses, including human immu-
nodeficiency virus type 1 and hepatitis A virus (18, 29). Al-
though MAb S109.8 likely recognizes an epitope within the
RBD, the site is located away from residues in direct contact
with ACE2. The mechanism of neutralization by S109.8 is
unknown, but we hypothesize that binding of S109.8 to the
RBD may result in either structural changes that affect its
binding to ACE2, blocking of structural changes in the RBD
needed for efficient binding to ACE2, or steric hindrance dur-
ing ACE2 binding, as has been described for poliovirus, avian
sarcoma-leukosis virus, and human papillomavirus (7, 53, 54).
The locations and mechanisms of neutralization for the
other MAbs identified in this study remain unknown, under-
scoring the need for more-detailed analysis of escape mutants
and the efficacy of protection in vivo.
We successfully used escape mutant analysis to identify key
residues involved in the neutralizing activities of two cross-
neutralizing human MAbs. Escape variant analysis has been
used previously to identify the importance of P462 in the neu-
tralization of SARS-CoV by MAb CR3014 (46) as well as to
identify epitopes for various other viruses, including influenza
virus (17). Although escape mutants can be helpful in identi-
fying important neutralizing residues, they compromise the use
of the MAb as prophylaxis or treatment. Previous studies with
human MAbs neutralizing SARS-CoV and rabies virus have
shown that the use of a MAb cocktail may circumvent this
problem (2, 46). Our data show that individual MAb escape
mutants can be efficiently neutralized by the other cross-neu-
tralizing MAbs and that these MAbs should therefore be used
as a cocktail to prevent the generation of escape mutants. This
application is especially useful given that we were unsuccessful
in isolating neutralization escape mutants against one of the
MAbs (S227.14).
The use of neutralizing MAbs in passive immunizations has
been well established (27, 39). This form of immunization has
the advantage of providing immediate protection in the ab-
sence of a humoral immune response and may be especially
advantageous for elderly populations, since they show in-
creased morbidity and mortality caused by infectious diseases
in general and SARS-CoV in particular (1, 4, 5, 44). This is
generally accepted to be due to a compromised senescent
immune system (1, 44), as demonstrated by the limited pro-
tection against a heterologous SARS-CoV in vaccinated aged
mice (8). Therefore, the use of MAbs shown to cross-neutral-
ize human and zoonotic SARS-CoV strains may be an attrac-
tive alternative for use in the elderly as well as in laboratory
personnel after accidental exposure.
Several studies have shown that MAbs and polyclonal sera
can effectively protect young mice from homologous SARS-
CoV replication in the lung (42, 43). These models evaluated
virus replication only in the absence of clinical disease, and the
aged-mouse model recapitulating human SARS-CoV infection
allows a more relevant evaluation of efficacy (34). We recently
developed lethal models of SARS-CoV bearing variant S gly-
coproteins that recapitulated the age-related highly pathogenic
phenotype observed in acute SARS cases in humans (37).
Aged mice have been used to test whether immune serum
protects from weight loss, reduces viral titers, and prevents
histopathologic changes in the lungs (51). However, to date no
MAbs have been tested in aged-animal models of SARS-CoV,
especially following heterologous challenge with lethal viruses.
These models have the advantage of testing treatment regi-
mens in the most vulnerable populations, the elderly, as well as
generally evaluating the efficacy of immunoprophylactic ther-
apy in this population.
In the present study, we tested the abilities of three broad-
spectrum human MAbs to cross-protect against challenge with
one homologous and three heterologous SARS-CoV isolates.
We showed complete protection against clinical disease and
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virus replication in the lungs of mice treated with S227.14 or
S230.15 and challenged with a late- or early-phase human
isolate. Interestingly, animals were also protected against clin-
ical disease after challenge with the palm civet isolate despite
the presence of high viral titers in the lung. Although animals
were not completely protected against viral replication on day
2 postinfection, no virus could be detected by day 5, thereby
reducing the chance of transmission. A cocktail of multiple
MAbs was as capable of protecting against lethal challenge as
the most potent individual MAbs, providing a strategy for
minimizing the emergence of MAb escape mutants (2, 46).
Aged animals were less effective at clearing heterologous
virus than were the younger animals. This may be due to an
impaired innate immune system in the elderly (1) or to differ-
ences in the efficiency of the human MAbs at reaching the lung
mucosa and neutralizing the virus. Bidirectional IgG transport
across epithelial barriers is mediated in part by the major
histocompatibility complex class I-related Fc receptor, which
has been shown to be downregulated by age (9). To our knowl-
edge, this is the first study to compare and document differ-
ences in passive immunization efficacy between young and
aged animals, potentially documenting an important clinical
consideration in the treatment of the elderly. The effect of age
on the efficacy of passive immunizations should be studied in
further detail, perhaps by evaluating antibody efficacy in pro-
gressively older animals challenged with lethal viruses.
Ideally, these antibodies could also be used in postinfection
treatment of SARS-CoV. MAb S230.15 could effectively pro-
tect against or reduce the clinical symptoms of SARS-CoV
infection only when mice were treated with the MAb 1 day
prior to challenge or on the day of challenge. This was partic-
ularly surprising because similar treatments were very success-
ful with H5N1 influenza virus infections in mice (41). However,
we used a much higher dose of SARS-CoV to challenge the
mice, and the SARS-CoV infection models are much more
acute than the model of influenza virus H5N1 infection in
mice. In addition, the murine Fc receptor has a relatively low
affinity for the human Fc portion, which may also explain the
difference in protection between S230.15 and S227.14 in young
mice challenged with the highly lethal MA15 virus. Therefore,
future experiments to assess the role of the Fc portion in the
effector neutralizing potential of the MAbs may be necessary.
Interestingly, mice treated at 2 or 3 days postchallenge did
reduce viral loads by clearing virus replication by day 4, but
these animals were not protected against clinical disease.
These data suggest that the clinical disease course is set within
the first 24 h of infection, since mice were not protected with
MAbs after this time and died even after virus had been
cleared. This is in agreement with observations of human
SARS cases, where a large subset of cases showed clinical
disease after virus clearance (14).
Our data show that cross-reacting MAbs exist that can effi-
ciently neutralize all human and zoonotic SARS-CoV isolates
reported to date. It is interesting that broadly neutralizing
MAbs were isolated at a late time point after infection (2
years), suggesting a long-lasting maintenance of potent SARS-
CoV-neutralizing MAbs in the B-cell memory repertoire,
which would protect survivors against epidemic and zoonotic
SARS-CoV emergence. While escape mutants could be gen-
erated against some of the MAbs, these could still be neutral-
ized by the other MAbs, stressing the importance of combina-
tion therapy. In addition, we showed that escape mutant
analysis coupled with a time-ordered panel of outbreak isolates
provides a novel set of reagents with which to map neutralizing
epitopes. These methods can potentially be used to identify
and characterize cross-neutralizing epitopes of novel emerging
viral pathogens. Cross-neutralizing epitopes will be important
targets for the development of a vaccine that protects against
the reemergence of SARS-CoV from its zoonotic reservoir.
These MAbs are attractive candidates for prophylactic treat-
ment of SARS-CoV infection, and further development should
include testing in larger-animal models of SARS-CoV infec-
tion such as ferrets and nonhuman primates, including trans-
mission models. We also showed the importance of testing
multiple heterologous SARS-CoV strains and the use of robust
animal models with multiple readouts, e.g., virus replication,
pathology, clinical signs, and mortality. These models will be
essential for successful vaccine development in aged popula-
tions. Finally, understanding the mechanisms of neutralization
may provide insight into the SARS-CoV entry process.
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